Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Tina Jiao"'
Autor:
Karen Young, Ting Xiong, Kaylen J. Pfisterer, Denise Ng, Tina Jiao, Raima Lohani, Caitlin Nunn, Denise Bryant-Lukosius, Ricardo Rendon, Alejandro Berlin, Jacqueline Bender, Ian Brown, Andrew Feifer, Geoffrey Gotto, Joseph A. Cafazzo, Quynh Pham
Publikováno v:
Communications Medicine, Vol 3, Iss 1, Pp 1-13 (2023)
Abstract Background Virtual nurse-led care models designed with health care professionals (HCPs) and patients may support addressing unmet prostate cancer (PCa) survivor needs. Within this context, we aimed to better understand the optimal design of
Externí odkaz:
https://doaj.org/article/3b34c9b7c1e64ed68ee63cbcf9ab6918
Autor:
Sasha Thomson, Louis Everest, Noah Witzke, Tina Jiao, Seanthel Delos Santos, Vivian Nguyen, Matthew C. Cheung, Kelvin K. W. Chan
Publikováno v:
Cancer Medicine, Vol 11, Iss 2, Pp 380-391 (2022)
Abstract Background We examined if oncology drug indications with high clinical benefit, as measured by the American Society of Clinical Oncology Value Framework (ASCO‐VF) and European Society for Medical Oncology Magnitude of Clinical Benefit Scal
Externí odkaz:
https://doaj.org/article/09021889f4774c11bd1d8949aeb37c50
Publikováno v:
Current Oncology, Vol 28, Iss 1, Pp 606-618 (2021)
Background: To determine the magnitude of difference between manufacturer-submitted and pan-Canadian Oncology Drug Review (pCODR) calculated incremental cost-effectiveness ratios (ICERs), incremental cost (ΔC), and incremental effectiveness (ΔE); t
Externí odkaz:
https://doaj.org/article/8ce479d71683474bae3a1defde9e3afd
Publikováno v:
Cancer Medicine, Vol 9, Iss 1, Pp 94-103 (2020)
Abstract Objectives Value‐based pricing of oncology drugs provides a best estimate for the price of a drug, as it relates to the benefits it provides for individual patients. To date, the impact of value‐based pricing to reference cost‐effectiv
Externí odkaz:
https://doaj.org/article/70595f09cd07476cb0b9bf25b3bb33be
Autor:
Karen Young, Ting Xiong, Denise Ng, Tina Jiao, Raima Lohani, Kaylen Pfisterer, Caitlin Nunn, Denise Bryant-Lukosius, Ricardo Rendon, Alejandro Berlin, Jacqueline Bender, Ian Brown, Andrew Feifer, Geoffrey Gotto, Joseph Cafazzo, Quynh Pham
Background: Approximately one in eight Canadian males will be diagnosed with prostate cancer. Longer survivorship horizons and resource constraints are leading to increasing strain on current models of specialist-led follow-up care delivery. Nurse-le
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4f03137196dc35a71e40c5e9ef6878d6
https://doi.org/10.21203/rs.3.rs-2924582/v1
https://doi.org/10.21203/rs.3.rs-2924582/v1
Autor:
Ting Xiong, Karen Young, Kaylen Pfisterer, Denise Ng, Raima Lohani, Tina Jiao, Caitlin Nunn, Denise Bryant-Lukosius, Ricardo Rendon, Alejandro Berlin, Jacqueline Bender, Ian Brown, Andrew Feifer, Geoffrey Gotto, Joseph Cafazzo, Quynh Pham
Background: Prostate cancer survivors (PCa) can experience a range of unmet needs over a long horizon of survivorship. Thin healthcare services and specialist-led follow-up care models may not adequately address these needs. Digitally mediated nurse-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::305bb7eb25ebaa99e3aeef806de6eb58
https://doi.org/10.21203/rs.3.rs-2925273/v1
https://doi.org/10.21203/rs.3.rs-2925273/v1
Autor:
Noah Witzke, Vivian Nguyen, Tina Jiao, Sasha Thomson, Louis Everest, Kelvin K. W. Chan, Matthew C. Cheung, Seanthel Delos Santos
Publikováno v:
Cancer Medicine, Vol 11, Iss 2, Pp 380-391 (2022)
Cancer Medicine
Cancer Medicine
Background We examined if oncology drug indications with high clinical benefit, as measured by the American Society of Clinical Oncology Value Framework (ASCO‐VF) and European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26c161145da0fa73db09ff1661ea1af9
https://doaj.org/article/09021889f4774c11bd1d8949aeb37c50
https://doaj.org/article/09021889f4774c11bd1d8949aeb37c50
Autor:
Saluja, Ronak1,2 ronak.saluja@mail.utoronto.ca, Tina Jiao1 tina.jiao@uwaterloo.ca, Koshy, Liza1 lkoshy@uwaterloo.ca, Cheung, Matthew1,2 Matthew.Cheung@sunnybrook.ca, Chan, Kelvin K. W.1,2,3,4 kelvin.chan@sunnybrook.ca
Publikováno v:
Current Oncology. Feb2021, Vol. 28 Issue 1, p606-618. 13p.
Publikováno v:
Cancer Medicine, Vol 9, Iss 1, Pp 94-103 (2020)
Cancer Medicine
Cancer Medicine
Objectives Value‐based pricing of oncology drugs provides a best estimate for the price of a drug, as it relates to the benefits it provides for individual patients. To date, the impact of value‐based pricing to reference cost‐effectiveness thr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98062bce9f26f38f24a83023c15cbb97
https://doaj.org/article/70595f09cd07476cb0b9bf25b3bb33be
https://doaj.org/article/70595f09cd07476cb0b9bf25b3bb33be
Publikováno v:
Current Oncology
Volume 28
Issue 1
Pages 60-618
Current Oncology, Vol 28, Iss 60, Pp 606-618 (2021)
Volume 28
Issue 1
Pages 60-618
Current Oncology, Vol 28, Iss 60, Pp 606-618 (2021)
Background: To determine the magnitude of difference between manufacturer-submitted and pan-Canadian Oncology Drug Review (pCODR) calculated incremental cost-effectiveness ratios (ICERs), incremental cost (&Delta
C), and incremental effectivenes
C), and incremental effectivenes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::863f32f385d2715e0f1d391e71294712